「ac」の検索結果
129件：1～5件目を表示
-
レボカバスチン点眼液0.025%「TS」
)-(3S ,4R )-1-[cis-4-cyano-4-(4-fluorophenyl) cyclohexyl]-3-methyl-4-phenylpiperidine-4- carboxylic acid monohydrochloride 分子式：C26H29FN2O2・HCl 分子量：456.98 性状：本品は白色もしくはほとんど白色の粉末である。 本品はギ酸にやや溶けやすく、メタノールに...
https://www.senju.co.jp/system/files/product_other_file/2024-03/levocabastine_202403_I.pdf -
General Announcement: September 3, 2024 Senju Pharmaceutical Co., Ltd. Acquisition of Marketing Approval for “ Mytear LUMIFY” Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr....
https://www.senju.co.jp/system/files/content_news/2024-08/ENG_20240903_0.pdf -
January 17, 2025 General Announcement: Senju Pharmaceutical Co., Ltd. Mochida Pharmaceutical Co., Ltd. Senju has Applied for Manufacturing and Marketing Approval in Japan for the novel Dry Eye Disease...
https://www.senju.co.jp/system/files/content_news/2025-01/ENG_20250117.pdf -
July 16, 2024 General Announcement: Senju Pharmaceutical Co., Ltd. Mochida Pharmaceutical Co., Ltd. Senju has successfully completed Phase III clinical trials in Japan for the novel Dry Eye Disease tr...
https://www.senju.co.jp/system/files/content_news/2024-07/ENG_20240716.pdf -
July 16, 2024 General Announcement: Senju Pharmaceutical Co., Ltd. Mochida Pharmaceutical Co., Ltd. Senju has successfully completed Phase III clinical trials in Japan for the novel Dry Eye Disease tr...
https://www.senju.co.jp/system/files/content_news/2024-07/ENG_20240716_0.pdf